PURE Bioscience Names Craig Johnson as Chief Financial Officer

PURE Bioscience PURE announces the appointment of Craig Johnson as Chief Financial Officer, effective August 1, 2011. Mr. Johnson has more than 15 years' experience as a senior financial executive in the healthcare industry. Mr. Johnson has been Chief Financial Officer of two publicly traded companies: NovaDel Pharma, a drug delivery company, and TorreyPines Therapeutics, a biopharmaceutical company. Prior to that, he was Chief Financial Officer and Senior Vice President of Operations for MitoKor, a drug discovery company. Mr. Johnson currently serves on the board of directors, and as chairman of the audit committees, of Ardea Biosciences and Adamis Pharmaceuticals, both of which are publicly traded biotechnology companies based in San Diego. Michael L. Krall, President and CEO of PURE Bioscience, said, “We are delighted to attract a professional of Craig's caliber to PURE. He is an outstanding financial and operations executive with a proven record in managing growth companies. He has the background and expertise to help PURE develop its many new business opportunities and execute our multi-faceted growth strategy.”